CLU and Alzheimer disease: Metabolic disturbances are increasingly recognized as key contributors to AD pathology, highlighted by significant alterations in brain lipids in AD patients and genetic risk factors associated with lipid metabolism, including APOE, TREM2, APOJ, PICALM, ABCA1, and ABCA7 (reviewed in [72]).